Loading organizations...
VectorY is an integrated gene therapy company that develops novel therapeutics for patients. The company's platform focuses on creating innovative vectorized antibodies, specifically targeting central nervous system (CNS), somatic disorders, and muscle diseases. Their approach leverages advanced scientific technologies to address conditions, particularly neurodegenerative diseases, by delivering therapeutic agents effectively within the body.
Founded in August 2020, VectorY established its operations in the Amsterdam Science Park. The company emerged from the insight into the significant therapeutic potential of vectorized antibodies, aiming to overcome limitations of traditional treatment modalities. This foundational premise drives their commitment to pioneering new solutions in gene therapy.
VectorY's primary focus is on individuals suffering from neurodegenerative diseases. The company's overarching mission is to improve the lives of these patients by developing transformative vectorized antibody treatments. They envision providing a longer, better quality of life through their innovative and integrated gene therapy solutions.
VectorY has raised $177.6M across 2 funding rounds.
VectorY has raised $177.6M in total across 2 funding rounds.
VectorY has raised $177.6M in total across 2 funding rounds.
VectorY's investors include Forbion, Philip Scheltens, ALS Investment Fund, BioGeneration Ventures, Insight Partners, Karin Kleinhans, Sander van Deventer, Alexander Vos, Eli Lilly and Company.
VectorY has raised $177.6M across 2 funding rounds. Most recently, it raised $140.0M Series A in November 2023.
| Date | Round | Lead Investors | Other Investors | Status |
|---|---|---|---|---|
| Nov 1, 2023 | $140M Series A | Forbion, Philip Scheltens | ALS Investment Fund, BioGeneration Ventures, Insight Partners, Karin Kleinhans | Announced |
| Jun 15, 2021 | $37.6M Seed | Sander VAN Deventer | Alexander VOS, ELI Lilly And Company | Announced |
VectorY is a biotechnology company based in Amsterdam, founded in 2020, that develops innovative gene therapies by combining antibodies with gene therapy to create long-lasting therapeutic solutions. Its core focus is on vectorized antibody treatments targeting neurodegenerative diseases such as ALS, Huntington’s, and Parkinson’s, as well as muscle disorders. VectorY’s proprietary platform uses adeno-associated virus (AAV)-based vectors to deliver these therapies, aiming to provide potentially disease-modifying treatments with a one-time administration. The company serves patients with complex, difficult-to-treat diseases and is advancing a pipeline of novel therapeutics with scalable manufacturing capabilities housed in its own GMP facility in Amsterdam[1][2][5][8].
VectorY was founded in August 2020 at the Amsterdam Science Park, seeded by Forbion, a leading European life sciences venture capital firm specializing in gene therapy investments. The company was co-founded by a team with deep expertise in gene therapy technology and manufacturing. Early on, VectorY established its own R&D and manufacturing infrastructure, including a state-of-the-art GMP facility designed for scalable AAV vector production. The company quickly secured its first corporate collaboration to develop vectorized antibody therapies targeting neuro-inflammation, marking a pivotal step in its growth and validation of its platform[1][3][5].
VectorY operates at the intersection of gene therapy and antibody therapeutics, riding the trend of precision medicine and advanced biologics for complex diseases. The timing is critical as neurodegenerative diseases remain largely untreatable with conventional methods, and gene therapy technologies have matured to enable safer, more scalable delivery. Market forces such as increasing investment in gene therapy, advances in AAV vector engineering, and growing demand for durable treatments favor VectorY’s approach. By integrating discovery, development, and manufacturing, VectorY influences the ecosystem by setting new standards for scalable gene therapy production and expanding the therapeutic reach of vectorized antibodies[1][2][5][8].
VectorY is poised for significant growth as it advances its pipeline through clinical development and scales manufacturing capacity. Future trends shaping its journey include continued innovation in AAV vector design, regulatory progress for gene therapies, and expanding applications of vectorized antibodies beyond neurodegeneration. Its influence may evolve from a pioneering biotech to a key player enabling broader access to gene therapies through cost-effective manufacturing and novel therapeutic modalities. As VectorY matures, it could redefine treatment paradigms for neurodegenerative and muscle diseases, fulfilling its mission to bring longer, better lives to patients worldwide[2][5][8].
